JP2024524433A - 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 - Google Patents

白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 Download PDF

Info

Publication number
JP2024524433A
JP2024524433A JP2023580804A JP2023580804A JP2024524433A JP 2024524433 A JP2024524433 A JP 2024524433A JP 2023580804 A JP2023580804 A JP 2023580804A JP 2023580804 A JP2023580804 A JP 2023580804A JP 2024524433 A JP2024524433 A JP 2024524433A
Authority
JP
Japan
Prior art keywords
pharma
alkyl
formula
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524433A5 (enExample
Inventor
シンハ，サントシュ・シー
プラサド，スリドハー・ゴビンダ
Original Assignee
プレックス ファーマスーティカルズ，インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレックス ファーマスーティカルズ，インク filed Critical プレックス ファーマスーティカルズ，インク
Publication of JP2024524433A publication Critical patent/JP2024524433A/ja
Publication of JP2024524433A5 publication Critical patent/JP2024524433A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023580804A 2021-06-28 2022-06-28 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 Pending JP2024524433A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163215818P 2021-06-28 2021-06-28
US63/215,818 2021-06-28
PCT/US2022/035336 WO2023278464A1 (en) 2021-06-28 2022-06-28 Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases

Publications (2)

Publication Number Publication Date
JP2024524433A true JP2024524433A (ja) 2024-07-05
JP2024524433A5 JP2024524433A5 (enExample) 2025-07-03

Family

ID=84692077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580804A Pending JP2024524433A (ja) 2021-06-28 2022-06-28 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤

Country Status (7)

Country Link
US (1) US20240327439A1 (enExample)
EP (1) EP4362923A4 (enExample)
JP (1) JP2024524433A (enExample)
CN (2) CN116963727A (enExample)
CA (1) CA3225704A1 (enExample)
MX (1) MX2024000116A (enExample)
WO (1) WO2023278464A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549533A (ja) * 2020-11-13 2023-11-27 プレックス ファーマスーティカルズ，インク 眼の状態を処置するための薬理剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP2023528761A (ja) * 2020-06-09 2023-07-06 エーエスエムエル ホールディング エヌ．ブイ． 内蔵同軸照明を備えたリソグラフィプリアライメント結像センサ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID19540A (id) * 1997-01-22 1998-07-23 Hoffmann La Roche Metode pembuatan turunan-turunan benzofenon
US20010044584A1 (en) * 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
AU2003243282B2 (en) * 2002-05-17 2008-05-01 Othera Holding, Inc. Amelioration of the development of cataracts and other opthalmic diseases
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
US9789091B2 (en) * 2013-03-14 2017-10-17 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
WO2022104383A1 (en) * 2020-11-13 2022-05-19 Plex Pharmaceuticals, Inc. Pharmacological agents for treating conditions of the eye

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
JP2023528761A (ja) * 2020-06-09 2023-07-06 エーエスエムエル ホールディング エヌ．ブイ． 内蔵同軸照明を備えたリソグラフィプリアライメント結像センサ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549533A (ja) * 2020-11-13 2023-11-27 プレックス ファーマスーティカルズ，インク 眼の状態を処置するための薬理剤

Also Published As

Publication number Publication date
MX2024000116A (es) 2024-06-19
EP4362923A1 (en) 2024-05-08
EP4362923A4 (en) 2025-03-19
CA3225704A1 (en) 2023-01-05
WO2023278464A1 (en) 2023-01-05
US20240327439A1 (en) 2024-10-03
CN116963727A (zh) 2023-10-27
CN117915900A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
CA2672985C (en) Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
JP6981694B2 (ja) 選択された抗コリン作用性双性イオンの使用
EA023607B1 (ru) Применение фотоусиливающих агентов при перекрестном сшивании роговицы
JP6771698B1 (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
US20240327439A1 (en) Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases
US20130317036A1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP7474706B2 (ja) ４－フェニル酪酸を含有する老視の治療または予防剤
JP7615139B2 (ja) 萎縮型加齢黄斑変性（ａｍｄ）又は萎縮型ａｍｄに続発する地図状委縮の治療用抗ｃ５剤
CN110496215A (zh) 一种治疗老视的水性滴眼液及其制备方法
JPH078805B2 (ja) 眼の発育の神経ペプチド制御
ES2860767T3 (es) Mirabegrón para el tratamiento de enfermedades retinianas
EP0556947A1 (en) Use of M1-selective antimuscarinic pyridobenzodiazepinones for the treatment and prevention of axial myopia
CN115768433A (zh) 含有司培前列素的医药制剂
WO2023278604A1 (en) Pharmacological agents for treating ophthalmic diseases
JP2023514732A5 (enExample)
US11433096B2 (en) Ophthalmic formulation and methods of use
WO2025090994A1 (en) Compositions for treating cataracts and/or presbyopia eye diseases
Karakashian et al. Niacin-induced cystoid macular edema
JPS6256130B2 (enExample)
WO1994003167A1 (fr) Remede contre la cataracte
KR19990080875A (ko) 갈라민을 유효성분으로 하는 근시예방 및 치료용 조성물
AU5998399A (en) Composition for treatment of light-injured retinal degeneration disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319